{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:45:41Z","timestamp":1762004741225},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"vor","delay-in-days":380,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.vhri.2015.08.002","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T13:45:22Z","timestamp":1443534322000},"page":"99-106","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Medical Costs Related to Enzyme Replacement Therapy for Mucopolysaccharidosis Types I, II, and VI in Brazil: A Multicenter Study"],"prefix":"10.1016","volume":"8","author":[{"given":"Fernanda Hendges de","family":"Bitencourt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiane Alves","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Eduardo","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jord\u00e3o Correa","family":"Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Boy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida Vanessa Doederlein","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2015.08.002_bib1","series-title":"The Metabolic and Molecular Basis of Inherited Disease","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.vhri.2015.08.002_bib2","doi-asserted-by":"crossref","unstructured":"Coutinho MF, Lacerda L, Alves S. Glycosaminoglycan storage disorders: a review. Biochem Res Int 2012;ID:471325.","DOI":"10.1155\/2012\/471325"},{"key":"10.1016\/j.vhri.2015.08.002_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10545-012-9559-x","article-title":"Brain magnetic resonance imaging findings in patients with mucopolysaccharidosis VI","volume":"36","author":"Azevedo","year":"2013","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.vhri.2015.08.002_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1750-1172-3-24","article-title":"The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK","volume":"3","author":"Moore","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.vhri.2015.08.002_bib5","unstructured":"Rede MPS. Brasil [homepage]. Available from: www.redempsbrasil.ufrgs.br\/. [Accessed December 14, 2014]."},{"key":"10.1016\/j.vhri.2015.08.002_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","article-title":"Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan","volume":"107","author":"Tanaka","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.vhri.2015.08.002_bib7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10545-005-0112-z","article-title":"Cumulative incidence rates of the mucopolysaccharidoses in Germany","volume":"28","author":"Baehner","year":"2005","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl. 84","key":"10.1016\/j.vhri.2015.08.002_bib8","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1590\/S0021-75572008000500003","article-title":"Treatment of inborn errors of metabolism","volume":"22","author":"Schwartz","year":"2008","journal-title":"J Pediatr (Rio J)"},{"key":"10.1016\/j.vhri.2015.08.002_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.vhri.2015.08.002_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.vhri.2015.08.002_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idurlsulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.vhri.2015.08.002_bib12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","article-title":"Long-term follow-up of endurance and safety during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulphatase","volume":"94","author":"Harmatz","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.vhri.2015.08.002_bib13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"Harmatz","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.vhri.2015.08.002_bib14","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with MN110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study","volume":"37","author":"Hendriksz","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.vhri.2015.08.002_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1590\/S0102-311X2012000300008","article-title":"Consequences of the judicialization of health policies: the cost of medicines for mucopolysaccharidosis","volume":"28","author":"Diniz","year":"2012","journal-title":"Cad Saude Publica"},{"key":"10.1016\/j.vhri.2015.08.002_bib16","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Portaria n 199, de 30 janeiro de 2014. Institui\u00e7\u00e3o da Pol\u00edtica Nacional de Aten\u00e7\u00e3o Integral \u00e0s Pessoas com Doen\u00e7as Raras. Di\u00e1rio Oficial da Uni\u00e3o 2014;1:44."},{"key":"10.1016\/j.vhri.2015.08.002_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16390","article-title":"The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders","volume":"16","author":"Wyatt","year":"2012","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.vhri.2015.08.002_bib18","first-page":"254","article-title":"Evaluation of orofacial motricity in patients with mucopolysaccharidosis: a cross-sectional study","volume":"85","author":"Turra","year":"2009","journal-title":"J Pediatr (Rio J)"},{"key":"10.1016\/j.vhri.2015.08.002_bib19","first-page":"37","article-title":"Functional capacity evaluation of patients with mucopolysaccharidosis","volume":"5","author":"Guarany","year":"2012","journal-title":"J Pedriatr Rehabil Med"},{"key":"10.1016\/j.vhri.2015.08.002_bib20","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Avalia\u00e7\u00e3o econ\u00f4mica em sa\u00fade: desafios para gest\u00e3o no Sistema \u00danico de Sa\u00fade\/Minist\u00e9rio da Sa\u00fade, Secretaria-Executiva, \u00c1rea de Economia da Sa\u00fade e Desenvolvimento. Bras\u00edlia: Editora do Minist\u00e9rio da Sa\u00fade, 2008."},{"key":"10.1016\/j.vhri.2015.08.002_bib21","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Portaria n\u00ba 3.916, de 30 de novembro de 1998. Aprova a Pol\u00edtica Nacional de Medicamentos. Di\u00e1rio Oficial da Uni\u00e3o 1998; 10 Nov."},{"key":"10.1016\/j.vhri.2015.08.002_bib22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ajmg.a.32320","article-title":"Mucopolysaccharidosis in Brazil: what happens from birth to biochemical diagnosis?","volume":"146A","author":"Vieira","year":"2008","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.vhri.2015.08.002_bib23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ymgme.2011.09.017","article-title":"Genetic studies in a cluster of mucopolysaccharidosis type VI patients in Northeast Brasil","volume":"104","author":"Costa-Motta","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"Suppl. 5","key":"10.1016\/j.vhri.2015.08.002_bib24","doi-asserted-by":"crossref","first-page":"v49","DOI":"10.1093\/rheumatology\/ker396","article-title":"Therapy for the mucopolysaccharidoses","volume":"50","author":"Valayannopoulos","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vhri.2015.08.002_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1542\/peds.2009-1728","article-title":"Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPSI: 5-year follow-up","volume":"125","author":"Gabrielli","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.vhri.2015.08.002_bib26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1651-2227.2011.02385.x","article-title":"Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up","volume":"101","author":"Tylki-Szymanska","year":"2010","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.vhri.2015.08.002_bib27","unstructured":"SIGTAP (Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM do Sistema \u00danico de Sa\u00fade \u2013 SUS) [internet homepage]. Available from: sigtap.datasus.gov.br\/. [Accessed December 10, 2014]."},{"key":"10.1016\/j.vhri.2015.08.002_bib28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ymgme.2012.05.003","article-title":"Biomarkers for the mucopolysaccharidoses: discovery and clinical utility","volume":"106","author":"Clarke","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.vhri.2015.08.002_bib29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","article-title":"Prevalence of lysosomal storage diseases in Portugal","volume":"12","author":"Pinto","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.vhri.2015.08.002_bib30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s004310050685","article-title":"Selective screening of 10,000 high-risk Brazilian patients for the detection of inborn errors of metabolism","volume":"156","author":"Coelho","year":"1997","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vhri.2015.08.002_bib31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199610033351405","article-title":"Clinical and biochemical manifestations of hyaluronidase deficiency","volume":"335","author":"Natowicz","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vhri.2015.08.002_bib32","first-page":"11","article-title":"A terapia de reposi\u00e7\u00e3o enzim\u00e1tica pode mudar a frequ\u00eancia de interven\u00e7\u00f5es m\u00e9dicas na mucopolissacaridose tipo I? Um estudo retrospectivo e explorat\u00f3rio","volume":"34","author":"de Bitencourt","year":"2014","journal-title":"Clin Biomed Res"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109915000552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109915000552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T22:58:28Z","timestamp":1567205908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109915000552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":32,"alternative-id":["S2212109915000552"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2015.08.002","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Costs Related to Enzyme Replacement Therapy for Mucopolysaccharidosis Types I, II, and VI in Brazil: A Multicenter Study","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2015.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}